

**Vijay Mahant, MS., PhD.**  
**vijaymedilite@msn.com**  
**(619)-992-3260**

---

Dr. Mahant graduated from LUT (UK) and he received his second post-doctorate from UT Health Science Center at Houston/MD Anderson, TX, USA). Dr. Mahant is a scientist and an entrepreneur with 30 years of experience in immuno- and molecular diagnostics. He has held executive positions and he is founder/co-founder of diagnostic companies with diverse experiences in RD, worked with hospitals /medical institutes such as Mayo Clinic ('87-'89, "New Generation" ultra-sensitive TSH test (evaluated and validated by Dr. George Klee , President of American Thyroid Association ) and worked (2005) with Long Beach Memorial Hospital in setting up a molecular diagnostic lab. Dr. Mahant has been involved in fund raisings, Initial Public Offerings (IPOs) and he has 25 issued patents and 15 patents pending; he has authored and/or co-authored publications. He has developed more than 35 products with multi million dollars in revenues. Dr. Mahant has managed intellectual property, including in and out licensing and he has experience in government regulations (FDA and foreign) and provided technical support for many of the products.

- 1983 PhD. in Medical Biochemistry, Loughborough University of Technology, Loughborough, United Kingdom. Thesis: Novel Homogeneous Luminescent Immunoassays.
- 1979 M.S. in Medicinal Chemistry, Loughborough University of Technology, Loughborough, UK. Thesis: Development of Homogeneous Fluorescence Immunoassays for Thyroxine and Triiodothyronine.
- 1978 B.S. in Biochemistry, University of Salford, Salford, United Kingdom.

Post-Doctoral Fellowships:

- 5/85-4/86 Mechanism of Cellular Differentiation by Inducers, University of Texas Health Science Center at Houston, TX.
- 2/84-4/85 Development of Semi-automated Chemiluminescence Immunoassay Based on Flow-injection Analysis, Loughborough University of Technology, Loughborough, UK.

Employment, Experience, Honors

- 7/94-Present MediLite Diagnostika, Inc., San Diego, CA.  
**CEO & Chairman**  
Founded MediLite, patented and developed chemiluminescence technologies and products for enzymes such as alkaline phosphatase. Successfully concluded agreements with a multinational company for the development of a rapid PSA assay based on MediLite's technology.
- 6/13-Present **OmniBiome (San Diego, CA)**  
**CSO**
- 7/13 **IZone Corporation** (Oceanside, CA)  
Co-founder and CSO  
Nutraceuticals for improving cognitive functions
- 03/14 **Star Genomics** (Carlsbad, CA)  
Cofounder and executive VP  
Focused on pharmacogenetic tests (Cardiology, pain, oncology, psychiatry and orthopedic) in a CLIA lab.

- 05/2011-Present **MedGen**  
 Co-founder and Chairman  
 Stem cell therapies (orthopedic and diabetes)
- 6/01- April 2007 AutoGenomics Inc., Carlsbad, CA  
**Executive Vice President, R&D.**
- 7/98-6/01 Qualigen Inc., Carlsbad, CA  
**CSO and Executive Vice President, R&D**  
 Responsible for all the R&D activities of Point-of-Care (POC) diagnostic tests.
- 7/93-7/94 Reflex Industries, Inc. and IEM Diagnostics, Inc., Santee, CA.  
**Executive Vice President, R&D**  
 Specializing in the development and manufacture of chemiluminescence and enzyme diagnostic kits for neonates (TSH, T4 and BCA etc).
- 6/92-Current AffyMed, CA.  
**Founder and Managing Director**  
 Consulting
- 8/90-5/92 Pantex, Santa Monica, CA.  
**Director, R&D**
- 2/89-8/90 Quest (Formerly, Nichols Institute) Diagnostics, San Juan Capistrano, CA.  
**Manager, R&D**  
 Headed the development of enzyme-mediated chemiluminescence immunoassays, managed a team of professional staff of eight including a PhD. Trained technicians, marketing and sales staff, and distributors.
- 9/88-2/89 Igen, Inc., Rockville, MD.  
**Group Leader**  
 Development of homogeneous electrochemiluminescence immunoassays for increasing throughput, sensitivity and stability of assays.
- 5/86-8/88 London Diagnostics, MN.  
**Project Leader**  
 Responsible for development of ultra-sensitive LumaTag TSH immunoassay. Transferred TSH assay from research to production . The LumaTag TSH became the "Gold Standard" in the industry and resulted in collaboration with Mayo (Rochester, MN)

**Patents:**

25 Patents issued and 15 patents pending.

**Book Chapters**

1. Mahant V. K. et al. The *INFINITI* System –an automated multiplexing microarray platform clinical laboratories, In: Microarray Methods and Applications-Nuts and Bolts. Eagerville:DNA Press, 2003:325-338.
2. Talpatra eta al. *INFINITI* System :An automated Multiplexing Protein Microarray Platform, In: Protein Microarrays:, edited by Mark Schena, Jones and Bartlett , Publishers,2005:353-364.
3. P.Kim et al. The Next Generation of Automated Microarray Platform for a Multiplexed CYP2D6 Assay, in :Biochips as Pathways to Drug Discovery, Edited by A. Carmen and G. Hardiman,CRC Press,2007:97-108

**Partial list of Publications/Abstracts :**

Over 17 articles published with the most relevant listed below:

- Flow-injection analysis with chemiluminescence detection in the determination of fluorescein and fluorescamine-labeled species. Mahant V.K et al, **Anal Chem. Acta**, 145: 203-206 1983.
- The development of an ultra-sensitive two-site chemiluminometric assay for thyroid stimulating hormone. *Vijay K. Mahant* and Ashok Patel, **Journal of Clinical Immunoassay**, 11 (1), 1988 (abstract).
- A two-site chemiluminescence immunoassay for human prolactin. *Vijay K. Mahant* et al, **Journal of Clinical Immunoassay**, 11 (1), 1988 (abstract).
- Luminescent Labels, A review of properties and chemistry. F. McCapra, *V.K. Mahant*, et al, **Journal of Bioluminescence and Chemiluminescence**, 2 (4) 1988 (abstract).
- A sensitive enzyme-mediated chemiluminescence immunoassay for intact human parathyroid hormone. *V.K. Mahant* et al, **Endocrine Society**, 1990 (abstract).
- Development of enzyme-mediated chemiluminescence immunoassay for thyroid stimulating hormone. K. Nozawa-Ung, *V.K. Mahant*, et al, **Journal of Clinical Immunoassay**, 1990 (abstract).
- Development of enzyme-mediated chemiluminescence immunoassays for human luteinizing hormone and follicle stimulating hormone. G. Odstrchel et al, *Bioluminescence and Chemiluminescence current status*, edited by P. Stanley and L. Kricka, John Wiley & Sons, 1991 (p127).
- A sensitive enzyme-mediated chemiluminescence immunoassay for human chorionic gonadotropin. *Vijay K. Mahant* et al, **Clinical Chemistry**, 36 (6), 1990 (abstract).
- Development of a sensitive and specific immunoradiometric assay for human luteinizing hormone based on a modified avidin and biotin. *Vijay K. Mahant* et al, **Journal of Clinical Immunoassay**, 14 (1), 1991 (abstract).
- Development of immunoradiometric assays for luteinizing and follicle stimulating hormone using avidin-coated paramagnetic particles. *V.K. Mahant* et al, **Journal of Clinical Immunoassay**, (1992) (abstract).
- Development of an immunoradiometric assay for human prolactin using avidin-coated paramagnetic particles. *V.K. Mahant* et al, **Clinical Chemistry**, 38 (6), 1992 (abstract).
- Development of a sensitive immunoradiometric assay for thyroid stimulating hormone using avidin-coated paramagnetic particles. *Vijay K Mahant* et al, **Journal of Clinical Immunoassay**, 16 (1), 1993 (abstract).
- Development of a sensitive enzyme immunoassay for neonatal thyroid stimulating hormone. *Vijay K Mahant* et al, **Clinical Chemistry**, 39 (6), 1993 (abstract).

#### **Symposia and Meetings:**

Use of flow-injection analysis in the development of ultra-sensitive luminescence immunoassays (Flow Analysis 11, International Symposium, Lund, Sweden, 1982) (symposium).